Peripheral expansion of myeloid-derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies

被引:2
|
作者
Torres-Ruiz, Jiram [1 ]
Absalon-Aguilar, Abdiel [1 ]
Alberto Reyes-Islas, Juan [1 ]
Cassiano-Quezada, Fabiola [1 ]
Mejia-Dominguez, Nancy R. [2 ]
Perez-Fragoso, Alfredo [1 ]
Luis Maravillas-Montero, Jose [2 ]
Nunez-Alvarez, Carlos [1 ]
Juarez-Vega, Guillermo [2 ]
Culebro-Bermejo, Alejandro [1 ]
Gomez-Martin, Diana [1 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Vasco de Quiroga 15,Belisario Dominguez Secc 16, Mexico City 14080, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Coordinac Invest Cient, Red Apoyo Invest, Mexico City, DF, Mexico
关键词
idiopathic inflammatory myopathies; myeloid-derived suppressor cells; PD-L1; arginase-1; cytokines; infectious damage; T-CELL; EXPRESSION; ADULT; PSORIASIS; SEVERITY;
D O I
10.1093/rheumatology/keac374
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the proportion of myeloid-derived suppressor cells (MDSCs), their expression of arginase-1 and programmed cell death ligand 1 (PD-L1) and their relationship with the clinical phenotype of patients with idiopathic inflammatory myopathies (IIMs). Methods We recruited 37 IIM adult patients and 10 healthy donors in Mexico City. We evaluated their clinical features, the proportion of MDSCs and their expression of PD-L1 and arginase-1 by flow cytometry. Polymorphonuclear (PMN)-MDSCs were defined as CD33(dim), CD11b(+) and CD66b(+) while monocytic (M)-MDSCs were CD33(+), CD11b(+), HLA-DR- and CD14(+). Serum cytokines were analysed with a multiplex assay. We compared the quantitative variables with the Kruskal-Wallis and Mann-Whitney U tests and assessed correlations with Spearman's rho. Results Most patients had dermatomyositis [n = 30 (81.0%)]. IIM patients had a peripheral expansion of PMN-MDSCs and M-MDSCs with an enhanced expression of arginase-1 and PD-L1. Patients with active disease had a decreased percentage {median 1.75% [interquartile range (IQR) 0.31-5.50 vs 10.71 [3.16-15.58], P = 0.011} of M-MDSCs and a higher absolute number of PD-L1(+) M-MDSCs [median 23.21 cells/mm(3) (IQR 11.16-148.9) vs 5.95 (4.66-102.7), P = 0.046] with increased expression of PD-L1 [median 3136 arbitrary units (IQR 2258-4992) vs 1961 (1885-2335), P = 0.038]. PD-L1 expression in PMN-MDSCs correlated with the visual analogue scale of pulmonary disease activity (r = 0.34, P = 0.040) and damage (r = 0.36, P = 0.031), serum IL-5 (r = 0.55, P = 0.003), IL-6 (r = 0.46, P = 0.003), IL-8 (r = 0.53, P = 0.018), IL-10 (r = 0.48, P = 0.005) and GM-CSF (r = 0.48, P = 0.012). M-MDSCs negatively correlated with the skeletal Myositis Intention to Treat Index (r = -0.34, P = 0.038) and positively with IL-6 (r = 0.40, P = 0.045). Conclusion MDSCs expressing arginase-1 and PD-L1 are expanded in IIM and correlate with disease activity, damage accrual and serum cytokines.
引用
收藏
页码:775 / 784
页数:10
相关论文
共 50 条
  • [1] Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease
    Kim, Yeon-Jeong
    Chang, Sun-Young
    Ko, Hyun-Jeong
    INTESTINAL RESEARCH, 2015, 13 (02) : 105 - 111
  • [2] Effects Of Exercise On The Expansion Of Myeloid-derived Suppressor Cells
    Garritson, Jacob
    Haughian, James M.
    Pullen, Nicholas A.
    Hayward, Reid
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2018, 50 (05): : 474 - 474
  • [3] Subsets, expansion and activation of myeloid-derived suppressor cells
    Ribechini, Eliana
    Greifenberg, Verena
    Sandwick, Sarah
    Lutz, Manfred B.
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2010, 199 (03) : 273 - 281
  • [4] Subsets, expansion and activation of myeloid-derived suppressor cells
    Eliana Ribechini
    Verena Greifenberg
    Sarah Sandwick
    Manfred B. Lutz
    Medical Microbiology and Immunology, 2010, 199 : 273 - 281
  • [5] Tristetraprolin limits age-related expansion of myeloid-derived suppressor cells
    Kwack, Kyu Hwan
    Zhang, Lixia
    Kramer, Elliot D.
    Thiyagarajan, Ramkumar
    Lamb, Natalie A.
    Arao, Yukitomo
    Bard, Jonathan E.
    Seldeen, Kenneth L.
    Troen, Bruce R.
    Blackshear, Perry J.
    Abrams, Scott I.
    Kirkwood, Keith L.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Insights into Myeloid-Derived Suppressor Cells in Inflammatory Diseases
    Kwak, Yewon
    Kim, Hye-Eun
    Park, Sung Gyoo
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2015, 63 (04) : 269 - 285
  • [7] Myeloid-derived Suppressor Cells in the Inflammatory Bowel Diseases
    Ostanin, Dmitry V.
    Bhattacharya, Dhruva
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (11) : 2468 - 2477
  • [8] Insights into Myeloid-Derived Suppressor Cells in Inflammatory Diseases
    Yewon Kwak
    Hye-Eun Kim
    Sung Gyoo Park
    Archivum Immunologiae et Therapiae Experimentalis, 2015, 63 : 269 - 285
  • [9] Peripheral Blood Myeloid-Derived Suppressor Cells Reflect Disease Status In Ipf
    Fernandez, I. E.
    Greiffo, F.
    Frankenberger, M.
    Heinzelmann, K.
    Neurohr, C.
    Hatz, R.
    Behr, J.
    Eickelberg, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [10] Myeloid-derived suppressor cells in inflammatory bowel disease:: A new immunoregulatory pathway
    Haile, Lydia A.
    Von Wasielewski, Reinhard
    Gamrekelashvili, Jaba
    Krueger, Christine
    Bachmann, Oliver
    Westendorf, Astrid M.
    Buer, Jan
    Liblau, Roland
    Manns, Michael P.
    Korangy, Firouzeh
    Greten, Tim F.
    GASTROENTEROLOGY, 2008, 135 (03) : 871 - 881